Basal forebrain atrophy in frontotemporal dementia.
Frontotemporal dementia
MRI, Basal forebrain
Volumetry
Journal
NeuroImage. Clinical
ISSN: 2213-1582
Titre abrégé: Neuroimage Clin
Pays: Netherlands
ID NLM: 101597070
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
11
2019
revised:
22
01
2020
accepted:
12
02
2020
pubmed:
7
3
2020
medline:
27
3
2021
entrez:
7
3
2020
Statut:
ppublish
Résumé
The basal forebrain is a subcortical structure that plays an important role in learning, attention, and memory. Despite the known subcortical involvement in frontotemporal dementia (FTD), there is little research into the role of the basal forebrain in this disease. We aimed to investigate differences in basal forebrain volumes between clinical, genetic, and pathological diagnoses of FTD. 356 patients with FTD were recruited from the UCL Dementia Research Centre and matched on age and gender with 83 cognitively normal controls. All subjects had a T1-weighted MR scan suitable for analysis. Basal forebrain volumes were calculated using the Geodesic Information Flow (GIF) parcellation method and were compared between clinical (148 bvFTD, 82 svPPA, 103 nfvPPA, 14 PPA-NOS, 9 FTD-MND), genetic (24 MAPT, 15 GRN, 26 C9orf72) and pathological groups (28 tau, 3 FUS, 35 TDP-43) and controls. A subanalysis was also performed comparing pathological subgroups of tau (11 Pick's disease, 6 FTDP-17, 7 CBD, 4 PSP) and TDP-43 (12 type A, 2 type B, 21 type C). All clinical subtypes of FTD showed significantly smaller volumes than controls (p ≤ 0.010, ANCOVA), with svPPA (10% volumetric difference) and bvFTD (9%) displaying the smallest volumes. Reduced basal forebrain volumes were also seen in MAPT mutations (18%, p < 0.0005) and in individuals with pathologically confirmed FTDP-17 (17%), Pick's disease (12%), and TDP-43 type C (8%) (p < 0.001). Involvement of the basal forebrain is a common feature in FTD, although the extent of volume reduction differs between clinical, genetic, and pathological diagnoses. Tauopathies, particularly those with MAPT mutations, had the smallest volumes. However, atrophy was also seen in those with TDP-43 type C pathology (most of whom have svPPA clinically). This suggests that the basal forebrain is vulnerable to multiple types of FTD-associated protein inclusions.
Sections du résumé
BACKGROUND
The basal forebrain is a subcortical structure that plays an important role in learning, attention, and memory. Despite the known subcortical involvement in frontotemporal dementia (FTD), there is little research into the role of the basal forebrain in this disease. We aimed to investigate differences in basal forebrain volumes between clinical, genetic, and pathological diagnoses of FTD.
METHODS
356 patients with FTD were recruited from the UCL Dementia Research Centre and matched on age and gender with 83 cognitively normal controls. All subjects had a T1-weighted MR scan suitable for analysis. Basal forebrain volumes were calculated using the Geodesic Information Flow (GIF) parcellation method and were compared between clinical (148 bvFTD, 82 svPPA, 103 nfvPPA, 14 PPA-NOS, 9 FTD-MND), genetic (24 MAPT, 15 GRN, 26 C9orf72) and pathological groups (28 tau, 3 FUS, 35 TDP-43) and controls. A subanalysis was also performed comparing pathological subgroups of tau (11 Pick's disease, 6 FTDP-17, 7 CBD, 4 PSP) and TDP-43 (12 type A, 2 type B, 21 type C).
RESULTS
All clinical subtypes of FTD showed significantly smaller volumes than controls (p ≤ 0.010, ANCOVA), with svPPA (10% volumetric difference) and bvFTD (9%) displaying the smallest volumes. Reduced basal forebrain volumes were also seen in MAPT mutations (18%, p < 0.0005) and in individuals with pathologically confirmed FTDP-17 (17%), Pick's disease (12%), and TDP-43 type C (8%) (p < 0.001).
CONCLUSION
Involvement of the basal forebrain is a common feature in FTD, although the extent of volume reduction differs between clinical, genetic, and pathological diagnoses. Tauopathies, particularly those with MAPT mutations, had the smallest volumes. However, atrophy was also seen in those with TDP-43 type C pathology (most of whom have svPPA clinically). This suggests that the basal forebrain is vulnerable to multiple types of FTD-associated protein inclusions.
Identifiants
pubmed: 32143137
pii: S2213-1582(20)30047-4
doi: 10.1016/j.nicl.2020.102210
pmc: PMC7058403
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102210Subventions
Organisme : Medical Research Council
ID : MR/J009482/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M008525/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M023664/1
Pays : United Kingdom
Organisme : Department of Health
ID : BRC149/NS/MH
Pays : United Kingdom
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Neuroimage. 2010 Nov 15;53(3):1070-6
pubmed: 20045477
Dement Geriatr Cogn Disord. 2008;25(2):178-85
pubmed: 18196898
Learn Mem. 2004 Jan-Feb;11(1):43-9
pubmed: 14747516
Neurosci Lett. 1984 Jan 27;44(1):37-42
pubmed: 6717850
Psychiatry Res. 2014 Mar 30;221(3):187-94
pubmed: 24434193
J Comp Neurol. 1988 Aug 22;274(4):483-515
pubmed: 2464621
Nature. 2006 Aug 24;442(7105):916-9
pubmed: 16862116
Acta Neuropathol. 2010 Jan;119(1):1-4
pubmed: 19924424
Lancet. 1977 Jan 22;1(8004):189
pubmed: 64712
J Neurol. 1999 Sep;246 Suppl 2:II6-15
pubmed: 10525997
Neuroimage. 2011 Jan 15;54(2):1735-42
pubmed: 20728544
Brain Res. 2017 Sep 1;1670:173-184
pubmed: 28652219
Arch Neurol. 2008 Feb;65(2):249-55
pubmed: 18268196
Neuron. 2011 Oct 20;72(2):257-68
pubmed: 21944779
Brain. 2012 Mar;135(Pt 3):794-806
pubmed: 22366795
Cereb Cortex. 2015 Jan;25(1):118-37
pubmed: 23964066
Am J Pathol. 2011 Nov;179(5):2533-50
pubmed: 21945902
J Comp Neurol. 1993 Apr 1;330(1):15-31
pubmed: 8468401
Acta Neuropathol. 2003 Feb;105(2):117-24
pubmed: 12536222
J Neurol. 2015 Dec;262(12):2635-42
pubmed: 26338813
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Neuroimage Clin. 2016 Dec 02;13:271-279
pubmed: 28018854
Neuropathol Appl Neurobiol. 2015 Dec;41(7):858-81
pubmed: 26041104
J Comp Neurol. 2016 Nov 1;524(16):3127-481
pubmed: 27418273
Cereb Cortex. 1996 May-Jun;6(3):470-81
pubmed: 8670672
Neuropathol Appl Neurobiol. 2015 Feb;41(1):24-46
pubmed: 25556536
Neuroimage. 2015 Jan 1;104:366-72
pubmed: 25255942
Neuroscience. 1999 Mar;89(1):73-89
pubmed: 10051218
Neuron. 2011 Oct 20;72(2):245-56
pubmed: 21944778
Am J Geriatr Psychiatry. 2007 Jan;15(1):84-7
pubmed: 17194818
J Comp Neurol. 2013 Dec 15;521(18):4124-44
pubmed: 23852922
Cortex. 2016 Oct;83:124-35
pubmed: 27509365
Neurobiol Learn Mem. 2003 Nov;80(3):245-56
pubmed: 14521867
Acta Neuropathol Commun. 2014 Dec 24;2:171
pubmed: 25539830
Neurology. 2011 Mar 15;76(11):1006-14
pubmed: 21325651
Ann Neurol. 2018 Nov;84(5):729-740
pubmed: 30255971
Drugs Aging. 2019 Aug;36(8):719-731
pubmed: 31201687
Neuroimage Clin. 2018 Feb 23;18:675-681
pubmed: 29876259
J Alzheimers Dis. 2014;40(3):737-42
pubmed: 24577458
J Neurosci. 2014 Mar 26;34(13):4509-18
pubmed: 24671996
J Neurochem. 1995 Feb;64(2):749-60
pubmed: 7830069
Neurobiol Aging. 1990 Jan-Feb;11(1):3-13
pubmed: 2183081
Brain. 2005 Nov;128(Pt 11):2626-44
pubmed: 16014654
Nature. 2006 Aug 24;442(7105):920-4
pubmed: 16862115
Neurosci Lett. 1983 Apr 11;36(2):195-9
pubmed: 6866327
Prog Brain Res. 2004;145:67-78
pubmed: 14650907
Dement Geriatr Cogn Disord. 2008;26(1):79-88
pubmed: 18617738
IEEE Trans Med Imaging. 2015 Sep;34(9):1976-88
pubmed: 25879909
Curr Opin Neurobiol. 1999 Apr;9(2):178-83
pubmed: 10322180
J Neuropathol Exp Neurol. 2016 May;75(5):397-407
pubmed: 26971127
Curr Opin Neurol. 2011 Dec;24(6):542-9
pubmed: 21986680